医药代表(全国)
百奥泰生物制药股份有限公司
- 公司规模:500-1000人
- 公司性质:合资
- 公司行业:制药/生物工程
职位信息
- 发布日期:2019-07-15
- 工作地点:广州
- 招聘人数:20人
- 工作经验:无工作经验
- 学历要求:招20人
- 语言要求:不限
- 职位月薪:8-40万/年
- 职位类别:销售代表
职位描述
岗位职责:
- 在公司政策和程序指引下传达医学信息,以合法合规方式达成公司指标;
- 及时提供市场信息并做出适当建议;
- 申请和报销学术会议;
- 与客户建立良好关系,保持公司形象;
- 收集区域内的竞品信息和行业政策动态,制定有效的应对计划;
- 能够就合规要求严于律己,严格管理自己的行为,确保日常工作全部遵循公司政策、行业准则以及相关法律法规政策,包括但不限于:积极完成合规培训;严守诚信,保持真实透明,如实准确报销真实发生且符合公司政策的费用;如对工作中遇有疑问主动向上级经理咨询。
任职条件:
- 大专或以上学历,医学、药学、生命科学等相关专业优先;
- 具有客户维护、开发和学术推广的成功经验和能力;
- 认可公司价值观,为人诚实正直;
- 具有良好的沟通能力和强烈的学习愿望;
- 工作积极,乐观向上,善于自我激励和承受压力;
- 具有团队合作精神,执行能力和意愿强;
- 熟练使用MS Office。
职能类别: 销售代表
公司介绍
百奥泰生物制药股份有限公司(股票代码:688177)秉承“创新只为生命”的理念,致力于开发新一代创新药和生物类似药,用于治疗肿瘤、自身免疫性疾病、心血管疾病以及其它危及人类生命或健康的重大疾病。公司已推动五款候选药物进入后期临床试验,其中格乐立(阿达木单抗)已在中国获批用于治疗类风湿关节炎、强直性脊柱炎、银屑病、克罗恩病和葡萄膜炎。此外,公司另有多款主攻肿瘤和自身免疫性疾病的候选药物处于不同的临床开发阶段。公司始终以患者的福祉作为首要核心价值,通过创新研发为患者提供安全、有效、可负担的优质药物,以满足亟待解决的治疗需求。欲了解更多信息,请访问公司官网或关注我们的微信公众号“百奥泰”。
Bio-Thera?Solutions, Ltd.a leading commercial-stage biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs, as well as biosimilars for existing branded biologics to treat a range of cancer and autoimmune diseases. As a leader in next-generation antibody discovery and engineering, the company has advanced five candidates into late stage clinical trials, one of which, QLETLI, a biosimilar to?Humira?(adalimumab), is available to patients with rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis,?Crohn's disease or uveitis in China. In addition, the company has multiple candidates in early clinical trials and IND-enabling studies, focusing on innovative targets in immuno-oncology and autoimmune diseases.
Bio-Thera?Solutions, Ltd.a leading commercial-stage biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs, as well as biosimilars for existing branded biologics to treat a range of cancer and autoimmune diseases. As a leader in next-generation antibody discovery and engineering, the company has advanced five candidates into late stage clinical trials, one of which, QLETLI, a biosimilar to?Humira?(adalimumab), is available to patients with rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis,?Crohn's disease or uveitis in China. In addition, the company has multiple candidates in early clinical trials and IND-enabling studies, focusing on innovative targets in immuno-oncology and autoimmune diseases.
联系方式
- Email:bd@bio-thera.com
- 公司地址:广州科学城开源大道11号科技企业加速器A6幢5楼 (邮编:510530)